The growth of specialty medications will challenge payers to improve patient access to treatment and ensure affordability. Payers will have to have targeted programs and complete solutions that ensure medication access, Dea Belazi, president and chief executive officer, AscellaHealth, said in an interview with Formulary Watch.
Specialty medicines will represent about 43% of global spending in 2027 and 56% of total spending in developed markets, according to the recently released report Global Use of Medicines 2023 from IQVIA.
To read more, click here.